Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.38 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HRAS | P01112 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311949 | 0.98 | TSHR (0.50) | AGXTTSHRNPC1RAB9AIDO1 | |
| Hydrochloric Acid SCHEMBL27812956 | 0.86 | AGXT (0.41) | AGXTTSHRNPC1RAB9AIDO1 | |
| SCHEMBL29222023 | 0.85 | AGXT (0.48) | AGXTTSHRNPC1RAB9AIDO1 | |
| SCHEMBL31634177 | 0.84 | RAB9A (0.54) | AGXTNPC1RAB9AIDO1MEN1 | |
| SCHEMBL31634208 | 0.84 | RAB9A (0.50) | AGXTNPC1RAB9AIDO1MEN1 | |
| SCHEMBL6334977 | 0.84 | POLB (0.46) | — | |
| SCHEMBL31634216 | 0.84 | MAOB (0.46) | AGXTNPC1RAB9AIDO1L3MBTL1 | |
| SCHEMBL31634175 | 0.84 | IDO1 (0.45) | NPC1RAB9AIDO1MEN1KMT2A | |
| SCHEMBL8340183 | 0.84 | TSHR (0.41) | AGXTTSHRNPC1RAB9AIDO1 | |
| SCHEMBL30665225 | 0.84 | AR (0.47) | TSHRNPC1RAB9AIDO1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627704-B | Preparation method of bazedoxifene | 艾瑞吉瑞股份公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-110627704-A | Preparation method of bazedoxifene | 艾瑞吉瑞股份公司 | 2019-12-31 | — | — | CN | disclosed |
| EP-2632916-A1 | NOVEL ANTI-CANCER AGENTS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2013-09-04 | — | — | EP | disclosed |
| US-8500990-B2 | Electrochemical biosensors based on NAD(P)-dependent dehydrogenase enzymes | NOVA BIOMEDICAL CORPORATION (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2012054978-A1 | NOVEL ANTI-CANCER AGENTS | LUDWIG INSTITUTE FOR CANCER RESEARCH LIMITED (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-2118058-B9 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA KS (CZ) | 2012-03-28 | — | — | EP | disclosed |
| EP-2118058-B1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA KS (CZ) | 2011-06-08 | — | — | EP | disclosed |
| CN-102001955-A | Method for synthesizing 4-benzyloxy aniline hydrochloride | XUZHOU RUISAI TECHNOLOGY INDUSTRY CO LTD | 2011-04-06 | — | — | CN | disclosed |
| US-20100270175-A1 | Electrochemical biosensors based on NAD(P)-dependent dehydrogenase enzymes | NOVA BIOMEDICAL CORPORATION (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA K.S. (CZ) | 2010-04-08 | — | — | US | disclosed |
| EP-1268849-A2 | REAGENTS AND METHODS FOR DETECTING A REDUCED COFACTOR | Lifescan, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| CN-1382151-A | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl)-1h-indol-5-ols | AMERICAN HOME PROD (US) | 2002-11-27 | — | — | CN | disclosed |
| US-20020132282-A1 | Test strips for detecting the presence of a reduced cofactor in a sample and methods for using the same | LIFESCAN, INC. | 2002-09-19 | — | — | US | disclosed |
| US-6420128-B1 | ABSORBENT MATERAL FOR USE IN THE DETETION OF PREFERENTIAL PARTICLES IN BLOOD | LIFESCAN, INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1212335-A1 | GLUCOPYRANOSIDES CONJUGATES OF 2-(4-HYDROXY-PHENYL)-1- 4-(2-AMIN-1-YL-ETHOXY)-BENZYL]-1H-INDOL-5-OLS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2002022855-A2 | TEST-STRIPS WITH POSITIVELY CHARGED MEMBRANES FOR TETRAZOLIUM BASED ASSAYS | LIFESCAN, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2001073114-A2 | REAGENTS AND METHODS FOR DETECTING A REDUCED COFACTOR | LIFESCAN, INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001019839-A1 | GLUCOPYRANOSIDES CONJUGATES OF 2-(4-HYDROXY-PHENYL)-1-[4-(2-AMIN-1-YL-ETHOXY)-BENZYL]-1H-INDOL-5-OLS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-0977743-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998049152-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | CYP19A1, CYP17A1, SHBG | BCHE 190/4885MAOB 85/4885AGXT 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.